AUPH — Aurinia Pharmaceuticals Inc. stock price, charts and financials

QT76Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.90
-0.06-0.35%
OverviewShort InterestFilings
AUPHQT76Aurinia Pharmaceuticals Inc.·NASDAQ
16.90-0.35%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BCRX-0.23%$8.68NKTR-1.84%$67.10GENB+0.12%$17.14OCUL-1.48%$9.99SLS-0.35%$11.49PVLA-2.44%$150.56TRVI-1.71%$14.95SRPT-2.71%$20.11
Snapshot
Index-P/E7.38EPS (ttm)2.29Insider Own15.68%Shs Outstand128.60MPerf Week4.97%
Market Cap2.25BForward P/E14.35EPS next Y1.18Insider Trans3.88%Shs Float126.24MPerf Month4.51%
Enterprise Value1.77BPEG0.37EPS next Q0.19Inst Own-Short Float7.11%Perf Quarter2.67%
Income314.00MP/S6.99EPS this Y-58.78%Inst Trans-Short Ratio6.22Perf Half Y20.11%
Sales311.00MP/B3.53EPS next Y24.79%ROA39.65%Short Interest8.98MPerf YTD5.96%
Book/sh4.78P/C4.91EPS next 5Y20.19%ROE59.00%52W High19.25 -12.21%Perf Year37.40%
Cash/sh3.44P/FCF11.93EPS past 3/5Y-ROIC21.27%52W Low10.34 63.44%Perf 3Y85.10%
Dividend Est.-EV/EBITDA9.39Sales past 3/5Y28.30% 41.44%Gross Margin90.36%Volatility3.02% 2.70%Perf 5Y-15.03%
Dividend TTM-EV/Sales5.71EPS Y/Y TTM5726.97%Oper. Margin48.39%ATR (14)0.48Perf 10Y686.05%
Dividend Ex-Date-Quick Ratio4.97Sales Y/Y TTM32.34%Profit Margin-RSI (14)60.69Recom2.27
Dividend Gr. 3/5Y-Current Ratio5.42EPS Q/Q75.00%SMA203.11%Beta1.58Target Price16.00
Payout0.00%Debt/Eq0.10Sales Q/Q18.57%SMA506.52%Rel Volume0.88Prev Close16.96
Employees128LT Debt/Eq0.10EarningsNov 03SMA2008.91%Avg Volume1.37MPrice16.90
IPO DateSep 03, 2014Option/ShortYes / YesEPS/Sales Surpr.16.67% 3.45%Net Debt/EBITDA-0.63Volume1,198,245Change-0.35%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC CapitalSector Perform$15 → $16
Dec-03-25DowngradeLeerink PartnersOutperform → Market Perform$16
Nov-07-25UpgradeJefferiesHold → Buy
Nov-05-25DowngradeRBC Capital MktsOutperform → Sector Perform
Nov-05-25DowngradeRBC CapitalOutperform → Sector Perform$15
Sep-06-24ReiteratedHC Wainwright & Co.Buy$26 → $13
May-02-24ReiteratedJefferies$6.00
Jan-04-23ReiteratedRBC CapitalOutperform$22 → $11
Nov-04-22DowngradeOppenheimerOutperform → Perform
Aug-09-22ReiteratedHC Wainwright & Co.Buy$30 → $26
Latest News· Times ET
Sep-16-26
Sep-16-2601:13AM
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got CompanyYahoo
Sep-04-26
Sep-04-2606:59PM
Immatics and 4 More Stocks See Action From Activist InvestorsYahoo
Aug-26-26
Aug-26-2607:01AM
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company StockBenzinga
Aug-20-26
Aug-20-2609:25AM
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Riseszacks.com
05:30AM
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drugbenzinga.com
Aug-19-26
Aug-19-2612:07PM
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037Benzinga
12:05PM
Aurinia Settles Patent Litigation with Tevabusinesswire.com
Aug-12-26
Aug-12-2612:56PM
Aurinia Pharmaceuticals Doubles Down On Its Pipelineseekingalpha.com
Aug-06-26
Aug-06-2606:51AM
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimateszacks.com
04:41AM
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M EstBenzinga
04:00AM
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progressbusinesswire.com
Jul-24-26
Jul-24-2601:00AM
Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS GrowthSeekingAlpha
Jul-23-26
Jul-23-2611:15AM
Playing The Biotech Breakout With Insidersseekingalpha.com
Jul-22-26
Jul-22-2608:20AM
The Credit Cycle Is Flashing YellowSeekingAlpha
Jul-06-26
Jul-06-2605:00AM
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritisgurufocus.com
Company

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue311283235——————
Cost of Goods Sold Incl. D&A313328——————
Gross Profit282250207——————
Selling, General and Administrative Excl. Other101102172——————
Research and Development393321——————
Other Operating Expense-101019——————
Operating Income150105-5——————
Interest Expense945——————
Unusual Expense
—————————
Non-Operating Income (Expense)181417——————
Net Income Before Taxes1611147——————
Income Taxes-154-1732——————
Consolidated Net Income3142876——————
Net Income From Continuing Operations3142876——————
Net Income3142876——————
EPS (Recurring)2.362.140.04——————
EPS (Basic, Before Extraordinaries)2.362.140.04——————
EPS (Diluted)2.292.070.04——————
EBITDA18912832——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio7.387.71228.50——————
Price To Sales Ratio7.067.555.46——————
Gross Margin90.6888.3488.09——————
Operating Margin48.2337.10-2.13——————
Net Margin100.96101.412.55——————
Shares Outstanding130134143——————
Market Capitalization2,1972,1371,284——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.12$16.87$13.62$10.37$7.12● Close Price0.00M2.10M4.20M6.30M8.40MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Robertson Stephen P.Chief Legal OfficerSep 10 '26Sale15.9511,939190,427588,848Sep 11
Robertson Stephen P.Chief Legal OfficerAug 21 '26Sale16.9720,975355,946600,787Aug 25
TANG KEVINChief Executive OfficerJun 02 '26Buy15.28206,0053,147,75613,044,106Jun 02
TANG KEVINChief Executive OfficerJun 01 '26Buy15.28343,6205,250,52012,838,101Jun 02
TANG KEVINChief Executive OfficerMay 29 '26Buy15.31264,9814,056,95112,494,481Jun 02
TANG KEVINDirectorMar 03 '26Buy14.22184,2082,619,43812,229,500Mar 03
TANG KEVINDirectorMar 02 '26Buy14.26199,3532,842,83312,045,292Mar 03
TANG KEVINDirectorFeb 27 '26Buy13.99516,4397,226,53511,845,939Mar 03
TANG KEVINDirectorAug 05 '25Buy11.68200,0002,336,00011,329,500Aug 05
TANG KEVINDirectorAug 04 '25Buy11.34100,0001,134,00011,129,500Aug 05
TANG KEVINDirectorAug 01 '25Buy10.121,000,00010,120,00011,029,500Aug 05
Keenan GregChief Medical OfficerAug 01 '25Sale10.5020,000210,000133,484Aug 05
Keenan GregChief Medical OfficerMar 07 '25Sale8.238,30568,350153,484Mar 07
TANG KEVINDirectorMar 04 '25Buy7.96748,0385,953,30410,029,500Mar 04
Robertson Stephen P.EVP, General CounselMar 04 '25Sale7.9257,607456,247509,276Mar 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.